10th May, 2026

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is to inform you that the US FDA conducted Good Manufacturing Practices (GMP) inspection of Piramal Pharma Limited's Sellersville (USA) facility from 4th May, 2026 to 8th May, 2026.

At the conclusion of the inspection, US FDA issued a Form-483, with three observations. At the closing meeting observations were recommended to be classified under VAI (Voluntary Action Indicated) by inspectors. None of the observation relate to data integrity.

The Company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines.

The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

This is for your information and records.

Thank you.

Yours truly,
For **Piramal Pharma Limited**
Maneesh Sharma
Digitally signed by Maneesh Sharma
Date: 2026.05.10 22:11:00 +05'30'
Maneesh Sharma
Company Secretary and Compliance Officer